FDA granted breakthrough therapy designation to Avidity Biosciences for a drug candidate targeting DMD.
2 reports, 2 independent
Updated Jul 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted breakthrough therapy designation to Avidity Biosciences for a drug candidate targeting DMD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Research advances have led to the approval of new therapies by the FDA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval expands patient access to therapies for ACCORD.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
Coverage
Newest first; wire copies grouped- Insider MonkeyAvidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy Designation We recently published 10 Shares Explode as Earnings Impress. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-pe
- PR NewswireAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping -- On track for